Arbutus Biopharma Corporation Stock Predictions
Currently predicting for Thu, 30 Mar 2023Trading levels for ABUS
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 3.15 | 5.11 % | |
| R2 | 3.11 | 3.65 % | ||
| R1 | 3.08 | 2.74 % | ||
| Current price: | 3.00 | |||
| Support | S1 | 2.99 | -0.187 % | |
| S2 | 2.97 | -1.09 % | ||
| S3 | 2.92 | -2.56 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 3.03 | 1.00 % | |
| R2 | 3.02 | 0.667 % | ||
| R1 | 3.01 | 0.333 % | ||
| Current price | 3.00 | |||
| Support | S1 | 2.95 | -1.67% | |
| S2 | 2.76 | -8.00% | ||
| S3 | 2.74 | -8.67% |
ABUS Predictions History
1 week ago
Auto.StockinvestBot predicted that
ABUS
for Mar. 16th is going
$2.98 (1.26%)
1 week ago
Robo.StockinvestBot predicted that
ABUS
for Mar. 16th is going
$3.00 (1.94%)
1 year ago
jrockstocks predicted that
ABUS
for 2021-12-02 is going
$8.00 (85.61%)
1 year ago
Fouad.Husseini.13932 predicted that
ABUS
for 2021-11-08 is going
1 year ago
eyeamzav.218890 predicted that
ABUS
for 2021-09-28 is going
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
